Ketoprofen Topical Patch, 20% in the Treatment of Pain Associated With Osteoarthritis Flare of the Knee

NCT ID: NCT00365586

Last Updated: 2020-02-19

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 300 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2006-08-31
• Study Completion Date: 2007-05-31

Brief Summary

The purpose of this study is to evaluate the effect of a ketoprofen topical patch on the pain associated with Osteoarthritis Flare of the Knee.

Detailed Description

This randomized, double-blind placebo-controlled parallel group study will be conducted with patients who have experienced a flare of osteoarthritis of the knee. At screening, patients whose pain is currently controlled by an analgesic will agree, after giving Informed Consent, to discontinue that analgesic. Eligible patients will be randomized (1:1 ratio) to receive double-blind treatment with either the ketoprofen topical patch or a matching placebo patch to be applied once daily for 28 days. Patients will return to the clinic on Days 7, 14, 21 and 28. At Day 28, patients may choose to open a 2 month open-label period.

Patients will rate their pain using the Knee Injury and Osteoarthritis Outcome Score (KOOS) which contains the WOMAC pain subscale. Patients will also complete an electronic diary in which pain intensity, pain relief, and quality of sleep ratings will be captured. In addition, rescue medication consumption data will be collected. Ibuprofen will be provided as prn rescue medication.

Conditions

Osteoarthritis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Interventions

Ketoprofen Topical Patch , 20%

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Males or females 18 years of age or older
• Diagnosis of osteoarthritis of the knee (unilateral or bilateral)
• Meet pain entry criteria
• Willing to discontinue use of all analgesic medications (including over-the-counter [OTC] analgesics) except those provided as the study treatment and rescue medication specifically for study purposes.

Exclusion Criteria

• Positive urine pregnancy test, pregnant or lactating.
• Have fibromyalgia, inflammatory arthritis, gout, pseudo-gout or Paget's disease
• Have any other type of clinically significant joint disease or have had joint replacement surgery at the index knee
• Have received either a corticosteroid injection in the 4 weeks preceding the screening visit or hyaluronic acid within 6 months of the screening visit
• Have a history or physical examination finding that is incompatible with safe participation in the study or study product use
• Are taking medications or other substances contraindicated due to the nature of the study medication or the potential for drug interactions.
• Have significant renal or hepatic impairment
• Are taking a sleep medication at a dose that has not been stable for at least 3 months

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

APR Applied Pharma Research s.a.

OTHER

Sponsor Role: lead

Principal Investigators

PPD

Role: PRINCIPAL_INVESTIGATOR

PPD Development, LP

Locations

PPD

Austin, Texas, United States

Countries

United States

Other Identifiers

EN3269-303

Identifier Type: -

Identifier Source: org_study_id